The company has three projects in the pipeline, including ONIVYDE, a new formulation of an anti-cancer drug approved by multiple regulatory bodies, PEP503, a nanoparticle radio-enhancer in a global pivotal trial for soft tissue sarcoma, and PEP06, a new chemical entity for cancer treatment in the pre-clinical stage. PharmaEngine adopts a no research, development only model and a networked pharma model for new drug development.